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In Brief
Kemper et al. have built a platform
composed of 89 metastatic melanoma
xenografts. Using this collection as a
resource, they identified a BRAFV600E
protein harboring a duplicated kinase
domain. A pan-RAF dimerization inhibitor
suppresses expansion of PDXs
expressing this BRAF mutant.
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The therapeutic landscape of melanoma is improving
rapidly. Targeted inhibitors show promising results,
but drug resistance often limits durable clinical
responses. There is a need for in vivo systems
that allow for mechanistic drug resistance studies
and (combinatorial) treatment optimization. There-
fore, we established a large collection of patient-
derived xenografts (PDXs), derived from BRAFV600E,
NRASQ61, or BRAFWT/NRASWT melanoma metas-
tases prior to treatment with BRAF inhibitor and after
resistance had occurred. Taking advantage of PDXs
as a limitless source, we screened tumor lysates for
resistance mechanisms. We identified a BRAFV600E
protein harboring a kinase domain duplication
(BRAFV600E/DK) in 10% of the cases, both in
PDXs and in an independent patient cohort. While
BRAFV600E/DK depletion restored sensitivity to BRAF
inhibition, a pan-RAF dimerization inhibitor effec-
tively eliminated BRAFV600E/DK-expressing cells.
These results illustrate the utility of this PDX platform
and warrant clinical validation of BRAF dimerization
inhibitors for this group of melanoma patients.
INTRODUCTION
Until 5 years ago, treatment options for metastatic melanoma
were limited to chemotherapy, which did not significantly
improve patient survival. However, the genetic characterization
of melanoma (Davies et al., 2002) has prompted the develop-C
This is an open access article under the CC BY-Nment of therapies targeting specifically the oncogenic drivers
of the disease. Approximately half of the patients diagnosed
with metastatic melanoma harbor an activating mutation in
BRAF, most commonly T1799A. This encodes the BRAFV600E
protein, which renders these patients eligible for treatment with
selective BRAF inhibitors. In clinical trials, the first of these inhib-
itors, vemurafenib, elicited partial or complete tumor regression
in the majority of patients (Chapman et al., 2011; Flaherty et al.,
2010).
Despite these promising results, while some patients show
remarkable durable responses to BRAF inhibition (BRAFi), the
majority show an initial response to vemurafenib but eventually
develop resistance (Solit and Rosen, 2014). Accounting for this
are a plethora of resistance mechanisms, including reactivation
of the MAPK pathway, the PI3K/AKT pathway, or both (Nazarian
et al., 2010; Paraiso et al., 2011; Poulikakos et al., 2011; Shi et al.,
2012, 2014a; Das Thakur et al., 2013; Wagenaar et al., 2014;
Wagle et al., 2011). As the majority of resistance mechanisms
cause reactivation of the MAPK pathway (Van Allen et al.,
2014), a logical next step was to determine the clinical benefit
of combinatorial treatment of a MEK inhibitor (e.g., trametinib
or cobimetinib) with a BRAF inhibitor (vemurafenib or dabrafe-
nib). The response to such combined treatment was significantly
more durable than what was seen for single BRAFi (Larkin et al.,
2014; Robert et al., 2015). Still also in the combination treatment
setting, resistance again limited overall survival benefit (Hugo
et al., 2015; Wagle et al., 2014). Because of these major chal-
lenges, there is a dire need to develop more effective (combina-
torial) treatment regimens.
Resistance to targeted drugs is mostly studied in in vitro cell
models (Basile et al., 2012; Nazarian et al., 2010; Poulikakos
et al., 2011; Vergani et al., 2011), but the use of long-term
cultured cancer cell lines has several limitations. First, they doell Reports 16, 263–277, June 28, 2016 ª 2016 The Author(s). 263
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not reliably predict the clinical effect of therapeutics (Burchill,
2006; Voskoglou-Nomikos et al., 2003). Second, the monolayer
character of cell culture does not recapitulate the 3D interactions
between stromal and cancer cells, which influence not only
the dynamics of tumor progression but also therapy response
(Straussman et al., 2012). Moreover, the establishment of 2D
cell lines from human cancers can induce irreversible changes,
including genetic aberrations (De Witt Hamer et al., 2008), alter-
ations in gene expression (Daniel et al., 2009), or dependencies
on certain signaling pathways (Clement et al., 2007). Importantly,
these properties are not restored upon xenografting of cell lines
(Daniel et al., 2009).
A clinically useful model would therefore be to implant tumor
fragments derived from patients immediately into mice, thereby
cancelling the opportunity for tumors to acquire alterations re-
sulting from in vitro culturing. Such patient-derived xenografts
(PDXs) already have been established for several tumor types,
including colon cancer (Bertotti et al., 2011), pancreatic cancer
(Rubio-Viqueira et al., 2006), breast cancer (DeRose et al.,
2011), and melanoma (Einarsdottir et al., 2014; Girotti et al.,
2016; Monsma et al., 2015; Das Thakur et al., 2013). Some of
these PDX models proved successful in large-scale assessment
of the effect of several (combinatorial) therapies and to identify
stratification markers, discriminating subgroups of tumors diver-
gently responding to targeted therapy (Bertotti et al., 2011; Gao
et al., 2015).
Therefore, we have established a model for metastatic mela-
noma in which the complex interactions between tumors and
at least some components of the tumor microenvironment are
maintained. Here we present a collection comprising 89 PDXs
established from human metastatic melanomas, which were ac-
quired either before the start of therapy or after the emergence of
resistance. This comprehensive PDX platform was analyzed for
biomarkers, chromosomal aberrations, RNA expression profiles,
mutational spectrum, genetic heterogeneity, and targeted drug
resistance patterns. In addition, we tested the utility of this plat-
form as a limitless source of patients’ tumor material by
screening for resistance mechanisms. Collectively, our results
demonstrate that this platform is highly suitable for studying
resistance, discovering additional drug targets for companion
treatment, and for preclinical studies of human melanoma in
general.
RESULTS
Establishment of a PDX Platform for Metastatic
Melanoma
Tumor specimens were obtained from patients diagnosed with
BRAFV600E, NRASQ61, or BRAFWTNRASWTmetastatic melanoma
during surgery or by fine-needle biopsy of mainly subcutaneous
lesions. Tumor fragments were immediately transplanted subcu-
taneously into immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ (NSG) mice with a success rate of 86%. This yielded a total
of 89 PDXs, comprising 73 BRAFV600E, 10 NRASQ61, and 6
BRAFWTNRASWT xenografts (Table S1). Our attempt to generate
cell lines from these PDX samples was successful in 30% of the
cases (Table S1). After a first passage in mice (.X1), tumor frag-
ments or digests could be propagated in vivo (.X2, Figure 1A)264 Cell Reports 16, 263–277, June 28, 2016or cryopreserved for later use. Passaging in mice led to a gradual
increase in the tumor outgrowth kinetics (Figure 1B), probably
due to loss of human stromal components, consistent with
PDXs derived from other tumor types (DeRose et al., 2011; Mon-
sma et al., 2012).
Stable Melanoma Marker Expression, Chromosomal
Aberrations, and Gene Expression upon In Vivo
Passaging of PDXs
We next determined the effect of passaging PDXs in vivo on
melanoma marker expression, chromosomal aberrations, and
RNA profiles. First, immunohistochemistry (IHC) for melanoma
markers Melan-A, S100, gp-100, and tyrosinase, commonly
used for the clinical diagnosis of melanoma, showed that mela-
noma marker expression remained stable when the patient’s tu-
morwas compared to two consecutive passages in vivo as PDXs
(Figure 1C; Figure S1).
Second, chromosomal aberrations, analyzed by array
comparative genomic hybridization (array CGH), revealed that
the genetic heterogeneity was captured in the PDXs (Figures
1D and 1E): passaging of M013 in mice revealed that at least
some of the genetic aberrations found in the parental tumor
were heterogeneous. For instance, the loss of chromosome
10, which was observed in the patient’s tumor, could be de-
tected in one of three first-passage PDXs only, suggesting that
chromosome 10 had not been lost in all parental tumor cells (Fig-
ure 1D). This is consistent with recent studies by us and others
showing that melanomas are highly heterogeneous (Kemper
et al., 2015; Shi et al., 2014b; Van Allen et al., 2014). Also
passaging of M003 in mice revealed a variable pattern, which
can be explained either by heterogeneity in the original tumor
or by loss of genomic variation upon in vivo passaging. Impor-
tantly, after the first passage, the chromosomal content was sta-
ble and highly similar to the parental chromosomal content
(Figure 1E).
Third, we analyzed gene expression patterns, comparing
patient samples to their corresponding PDXs. We obtained sam-
ples for PDX establishment from four different patients, with
tumor samples taken either before the start of vemurafenib treat-
ment or after a patient had acquired therapy resistance (indi-
cated by R). RNA was isolated from both patients’ tumors
and PDXs and gene expression profiling was done by RNA
sequencing. Hierarchical clustering of all samples was per-
formed, resulting in a clustering that revealed a high concor-
dance in gene expression between the patient samples and their
corresponding PDXs (Figure 1F).
Together, these data show that, during the passaging of hu-
man melanomas in mice, the phenotypic and genetic character-
istics are well preserved, yielding a collection of PDXs closely
resembling the original patients’ tumors.
Clinical History of Patients fromMatched Pre- and Post-
vemurafenib PDX Pairs
We acquired a set of six matched PDX pairs, representing tumor
material from patients both before the start of treatment with ve-
murafenib and after resistance had occurred (indicated by R).
We illustrated the treatment schedule, the location of the lesion
from where material was obtained for xenografting, and the
Figure 1. Stable Melanoma Marker Expres-
sion, Chromosomal Aberrations, and Gene
Expression upon In Vivo Passaging of PDXs
(A) Tumor fragments derived from biopsies or
surgical excisions were transplanted subcutane-
ously into NSGmice. After first passage (.X1), PDX
fragments were passaged into a next set of mice
(.X2).
(B) Speed of tumor outgrowth during passaging,
shown for two different PDXs. Colors represent
single PDX (.X1) passaged into a next set of three
mice (.X2).
(C) H&E stainings and IHC stainings for MelanA,
S100, gp-100, and tyrosinase were performed on
the parental tumor and two subsequent passages
of PDXs (X1 and X2). Scale bars indicate 100 mm.
(D) Copy-number profiles, based on array CGH,
show the parental tumor (P) M013 and two PDX
passages (the X2 passage was established from
the third X1 PDX).
(E) Copy-number profiles, based on array CGH,
show the parental tumor (P) M003 and two
PDX passages (the X2 passages are next to their
own X1-passaged PDX). Blue, deletion; red,
amplification.
(F) Hierarchical clustering of RNA-sequencing
data performed on patient samples and PDXs
derived of these samples, after filtering as
described in the Supplemental Experimental Pro-
cedures, is shown.specific response of these lesions to vemurafenib in Figure S2. In
four patients, the resistant lesions, from which post-treatment
PDXs were derived, either initially responded to vemurafenib
before acquiring resistance (M009R, M026R, and M048R1; Fig-
ure S2) or emerged as new lesions during treatment (M029R and
M048R2; Figure S2). Therefore, this group of PDXs was labeled
acquired resistant. One matched pair (M005) was derived from a
patient who was still responding to vemurafenib when the post-
treatment sample was obtained, and was therefore categorized
as on treatment. The sixth PDX pair was acquired from a patient
(M019) who progressed immediately on vemurafenib treatment,
qualifying these melanomas as intrinsic resistant (Figure S2).CeVemurafenib-Resistant PDXs
Commonly Display MAPK Pathway
Reactivation
Several groups, including ours, have
demonstrated that the MAPK pathway
and, to a lesser extent, the PI3K pathway
are commonly reactivated in vemurafe-
nib-resistant melanomas (Kemper et al.,
2015; Shi et al., 2014b; Van Allen et al.,
2014). To determine whether this was
recapitulated in our matched PDX
series, we performed immunoblotting for
phosphorylated ERK (p-ERK) and AKT
(p-AKT). Indeed, all four acquired resis-
tant PDXs from the matched pair set
had reactivated p-ERK (Figure 2A), which
was confirmed by IHC (Figure S3A).Only one PDX pair, namely M048, also showed reactivated
p-AKT (Figure 2A). As expected, the PDX of the intrinsically resis-
tant patient M019 already showed elevated p-ERK and p-AKT
levels in the pre-treatment setting, while p-ERK was relatively
low in the PDX from the on-treatment patient (Figure 2A;
Figure S3A).
Previously, we and others have shown that acquired resis-
tance to BRAFi is effectively brought about by the loss of
expression of microphthalmia-associated transcription factor
(MITF) (Konieczkowski et al., 2014; M€uller et al., 2014).
Consistent with this, we observed decreased expression
of MITF in three acquired resistant post-vemurafenib PDXsll Reports 16, 263–277, June 28, 2016 265
Figure 2. Vemurafenib-Resistant PDXs Commonly Display MAPK Pathway Reactivation and Have Distinct Resistance Mechanisms
(A) Immunoblotting of all six matched PDX pairs for factors in the MAPK pathway in pre-vemurafenib and post-relapse PDXs. Asterisks indicate PDXs that were
xenografted in mice that received PLX4720 chow.
(B) Copy-number profiles for matched PDX pairs, determined by CopywriteR, are shown.
(legend continued on next page)
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(M009R.X1, M026R.X1, and M048R.X1; Figure 2A). Reduced
expression of MITF coincides with upregulation of one or
multiple receptor tyrosine kinases (RTKs), such as EGFR,
PDGFR, and, most commonly, AXL (Konieczkowski et al.,
2014; M€uller et al., 2014), which was well recapitulated in
these matched acquired resistant PDXs (Figure 2A). Only
M029R.X1 displayed increased expression of MITF expres-
sion upon acquired resistance (Figure 2A), which also pre-
viously has been reported as a resistance mechanism to
MAPK pathway inhibition (Garraway et al., 2005; M€uller
et al., 2014).
In conclusion, our series of matched PDXs captures the resis-
tance biomarkers that are commonly seen in drug-resistant
melanomas in patients.
Identification of Resistance Mechanisms in Matched
PDX Pairs
To uncover the cause of resistance in the matched PDX pairs,
we performed whole-exome sequencing (WES) on genomic
DNA (gDNA) derived from all matched PDXs. The level of
tumor infiltration by mouse stroma was determined by a
mouse pathologist via analysis of formalin-fixed paraffin-
embedded (FFPE) H&E stainings of these PDXs, revealing
that most PDXs contained >80% of tumor cells (Table S2).
XenofilteR (R.J.C.K. and O.K., unpublished data) was used
to remove all sequence reads that originated from mouse
DNA. Copy-number profiles were generated from the filtered
WES data by CopywriteR (Kuilman et al., 2015) (Fig-
ure 2B). This analysis revealed that pre- and post-vemurafenib
PDXs had highly similar DNA copy-number profiles, although
some variation was observed. This could result from inter-tu-
mor heterogeneity, as most pre- and post-vemurafenib PDXs
were not derived from the same patient lesion (Figure S2B).
When analyzing copy-number aberrations (CNAs) in more
detail, we detected a BRAFT1799A amplification, an estab-
lished resistance mechanism (Shi et al., 2014b; Das Thakur
et al., 2013; Van Allen et al., 2014), in the resistant
M009R.X1, but not in the pre-treatment PDX (Figure 2C,
top panel). This amplification was validated by qPCR on
gDNA (Figure 2C, bottom panel). None of the other resistant
PDXs displayed an amplification of BRAFT1799A (Figures S3B
and S3C).
Next we analyzed the presence of mutations in the matched
PDX pairs (Figure 2D). The BRAFi resistance-inducing muta-
tion NRASQ61K (Nazarian et al., 2010) was detected in two
of the post-vemurafenib PDXs (M026R.X1 and M029R.X1)
and was confirmed by Sanger sequencing (Figures S4A
and S4B). In M048R2.X1, a mutation in AKT3 (L51R)
(Catalogue of Somatic Mutations in Cancer [COSMIC]:
COSM309035) was detected and confirmed by Sanger
sequencing (Figure S4C). This mutation has not been vali-
dated yet as a cause of resistance, but two other previously
described resistance-conferring mutations, namely AKT3E17K(C) Amplification of the genomic region containing BRAFT1799Awas identified in M
gDNA (bottom panel). CRAF was included as a negative control. CT values were
(D) Mutation matrix for matched PDX pairs, comparing pre-vemurafenib and post
one mutation.and AKT1Q79K (Shi et al., 2014a, 2014b), are located within
the same pleckstrin homology (PH) domain as AKT3L51R.
These mutations induce (re)localization of AKT to the
membrane, causing constitutive activation of the PI3K/AKT
pathway (Parikh et al., 2012). The M048R2.X1 PDX, harboring
this AKT3L51R mutation, indeed displays highly activated AKT
(Figure 2A), suggesting that this mutation activates the kinase
activity.
In summary, we have identified BRAFT1799A amplification and
NRASQ61K and AKT3L51R mutations as the likely causes for ve-
murafenib resistance in our matched acquired resistant PDX
pairs, capturing themutational spectrum seen in resistant human
melanomas.
Validation of Resistance to BRAFi In Vivo in Matched
PDX Pairs
The next step was to confirm that PDXs derived from vemura-
fenib-naive BRAFV600E lesions were responsive to BRAFi
in vivo, in contrast to PDXs from vemurafenib-resistant mela-
nomas. We first analyzed the response to the BRAFi dabra-
fenib of the matched M026 PDX pair. The treatment-naive
M026.X2 melanoma was highly sensitive to BRAFi, resulting
in reduced growth and a decrease in p-ERK abundance
upon BRAFi (Figures 3A and 3B; Figure S4D). In contrast,
M026R.X2, a PDX derived from a vemurafenib-resistant lesion
from the same patient in which we identified a NRASQ61K mu-
tation as the resistance mechanism (Figures S4A and S4B),
was completely resistant to BRAFi (Figure 3A). Consistently,
p-ERK levels of M026R.X2 were unaffected by BRAFi (Fig-
ure 3B). A similar pattern was observed for the matched
M029 PDX pair: treatment-naive melanoma M029.X2 re-
sponded well to BRAFi along with p-ERK inhibition, whereas
tumor outgrowth of NRASQ61K mutant M029R.X2 and its
p-ERK levels were unaffected by BRAFi (Figures 3A and 3B;
Figure S4D). Of note, the growth rate of the (untreated)
M029R.X2 was much slower than that of its treatment-naive
counterpart M029.X2.
This behavior was different for matched pair M009.X2/R.X2, in
which the presence of the BRAFT1799A amplification correlated
with therapy resistance. For this PDX set, expansion of the treat-
ment-naive M009.X2 melanoma was reduced upon BRAFi and
p-ERK levels decreased, as expected (Figures 3A and 3B; Fig-
ure S4D). However, BRAFi also slowed down the growth
and decreased p-ERK levels of M009R.X2, which was derived
from a vemurafenib-resistant lesion (Figures 3A and 3B; Fig-
ure S4D). This coincided with two interesting observations. First,
M009R.X2 grewmuch faster thanM009.X2. Therefore, in spite of
the notable effect of BRAFi, M009R.X2 continued to grow expo-
nentially. Second, expression of BRAFV600E, although already
highly expressed in M009R.X2 when compared to M009.X2,
was even further increased upon BRAFi (Figures 3C and 3D).
The cause for this is unknown but could reflect either a dosage
change in the BRAFT1799A gene or selection for a subpopulation009R.X1 (top panel). Validation of this amplification was performed by qPCR on
normalized to LINE.
-relapse tumors. Number of mutations is indicated; each black line represents
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Figure 3. Validation of Resistance to BRAFi In Vivo in Matched PDX Pairs
(A) Tumor dynamics of matched PDX pairs upon treatment with 30mg/kg dabrafenib (n = 8 tumors/group). Graphs represent fold change in tumor volume relative
to the tumor volume at treatment initiation. Unpaired t test was performed at the last time point (*p < 0.05 and **p < 0.01). Error bars indicate SD.
(legend continued on next page)
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Figure 4. Mutational Characterization of the
PDX Panel
(A) Targeted sequencing for 360 cancer genes was
performed on 47 PDXs, and WES was performed
on an additional six PDXs. Copy number profiles
were derived from these data. PDXs were
grouped in pre-BRAF inhibitor treatment (pre-
treatment), BRAF inhibitor-resistant (post-ve-
murafenib), intrinsic resistant, NRASQ61 mutant
(NRAS), and BRAFWTNRASWT PDXs and PDXs
derived from five different lesions for a single pa-
tient after tumor-infiltrating lymphocytes therapy
(post-TIL).
(B) Mutation matrix for 11 known melanoma driver
genes. Total number of mutations per 1 Mb and
the percentage of mutations with a C > T are
indicated below the mutation matrix.with super-amplification of BRAFT1799A. Additionally, this would
suggest that the BRAF amplification and the resulting resistance
can be dynamic, as has been suggested by others (Das Thakur
et al., 2013).
These results demonstrate concordance between drug re-
sponses in patients and their corresponding PDXs, and they
illustrate that the therapy response can be either stable or
dynamic.(B) Immunoblotting for p-ERK on matched PDX pairs, treated with and without dabrafenib (each lane repres
shown.
(C) The BRAFT1799A amplification was validated by qPCR on gDNA. CRAF was included as a negative cont
indicate SD.
(D) Stainings for BRAFV600E on M009.X2 and M009R.X2, treated with and without BRAF inhibitor. Scale bars
CeMutational Characterization of the
PDX Panel
In addition to six matched PDX pairs, the
collection comprises an additional 76
melanoma PDXs. Targeted sequencing
using a 360-cancer gene panel was per-
formed for more than half of these. The
47 PDXs comprise the following: (1)
BRAFV600E PDXs derived from vemurafe-
nib-naive or -resistant melanomas, (2)
NRASQ61 PDXs, (3) BRAFWT/NRASWT
PDXs, and (4) a set of five PDXs derived
from different lesions of one patient
who received tumor-infiltrating lympho-
cyte (TIL) therapy. Additionally, for six
PDXs, comprising three NRASQ61 and
three BRAFWTNRASWT PDXs, WES was
performed.
UsingCopywriteR,wegenerated copy-
number profiles from the sequencing
data (Figure 4A). These profiles revealed
a CNA pattern typical of melanoma,
including gain of chromosome 7, where
BRAF is located, and loss of chromosome
10, which harbors the tumor suppressor
gene PTEN, both established driversof melanomagenesis. Next we analyzed which mutations are
present in our PDX panel, focusing on mutations in the 15
driver genes on which the molecular classification of mela-
nomas has been described previously (Cancer Genome Atlas
Network, 2015) (Figure 4B). For 11 of 15 driver genes, mutations
were observed in the 53 PDX samples. The complete list of
mutations identified by targeted sequencing is provided in
Table S3.ents a tumor derived from an individual mouse), is
rol. CT values were normalized to LINE. Error bars
indicate 100 mm.
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Figure 5. PDXs Derived from Vemurafenib-
Resistant Melanomas Harbor a Plethora
of Established Clinical Resistance Mecha-
nisms
(A) Immunoblotting for p-ERK and p-AKT to detect
reactivation of the MAPK pathway and/or the
PI3K/AKT pathway in the post-vemurafenib PDXs.
Vinculin was used as a loading control.
(B) Immunoblotting to detect previously described
resistancemechanisms in post-vemurafenib PDXs.
Vinculin was used as a loading control.
(C) Analysis of BRAFT1799A amplification by qPCR
on gDNA of all post-vemurafenib PDXs is shown.
(D) DNA copy-number profiles revealed amplifi-
cation of the region containing MITF in two inde-
pendent PDXs.PDXs Derived from Vemurafenib-Resistant Melanomas
Harbor a Plethora of Established Clinical Resistance
Mechanisms
In the panel of 53 sequenced PDXs (Table S4), 19 were derived
from BRAFV600E metastatic melanomas that had acquired resis-
tance to vemurafenib. We analyzed this PDX set for the pres-
ence of known resistance mechanisms. As discussed above,
resistance to vemurafenib is commonly associated with
reactivation of the MAPK pathway and/or the PI3K/AKT
pathway. Concordantly, when we determined the correspond-
ing biomarker levels in these PDXs, we found that, in most,
either p-ERK or p-AKT was highly induced (Figure 5A;
Figure S5A).
Next we analyzed BRAF expression by immunoblotting
to detect alternative splice variants, which also are known
to render melanomas refractory to BRAFi. These variants splice
out the RAS-binding domain (RBD) of BRAF (encoded by exons
3–5), inducing dimerization of BRAF and downstream signaling
without the need to be activated by RAS (Poulikakos et al.,270 Cell Reports 16, 263–277, June 28, 20162011). Several splice variants have been
described to induce resistance, i.e.,
61-kDa (exons 4–10), 48-kDa (exons
2–8), and 41-kDa (exons 2–10) variants
(Poulikakos et al., 2011). Using two
different antibodies, recognizing either
the N-terminal (BRAFNT, epitope en-
coded by exons 2–3) or the V600E re-
gion (BRAFV600E, epitope in exon 15), we
detected these different splice variants
in several PDXs (Figure 5B).
We also identified other previously
detectedandvalidated resistancemecha-
nisms in the post-vemurafenib PDX panel,
including hyperactivation of c-MET (Ver-
gani et al., 2011), EGFR overexpression
(Sun et al., 2014), loss of PTEN (Paraiso
et al., 2011) (Figure 5B), amplification
of BRAFT1799A (Shi et al., 2014b) (Fig-
ure 5C), and amplification of MITF
(Garraway et al., 2005; Van Allen et al.,
2014) (Figure 5D). Additionally, usingthe targeted sequencing data, we found known BRAF inhibitor
resistance-conferring mutations, including MAP2K1E203K (Niko-
laev et al., 2011), BRAFL505H (Wagenaar et al., 2014), NRASQ61K
(Nazarian et al., 2010), and PIK3CAE545K (Shi et al., 2014b)
(Table S5).
Through a combination of mutational data with biochemical
analyses, the cause of resistance was resolved for 13 of the 19
PDXs derived from patients with acquired resistance to vemura-
fenib. This also revealed that some PDXs harbor multiple resis-
tancemechanisms (Table S5). For example, M056R.X1 harbored
a MAP2K1E203K mutation, alternative BRAF splicing, as well as
EGFR overexpression, indicating that resistance mechanisms
can be heterogeneous (Kemper et al., 2015; Shi et al., 2014b).
Our data show that this heterogeneity is captured and main-
tained in PDXs.
To summarize, this set of post-vemurafenib PDXs harbors
a wide range of resistance mechanisms, closely recapitulating
clinical samples. Some PDXs harbored multiple resistance
mechanisms, a phenomenon commonly seen in melanoma,
indicating that the heterogeneity of resistance can bemaintained
in these PDX models.
PDXs Derived from Vemurafenib-Resistant Patients
Express a BRAFV600EMutant Harboring a Kinase Domain
Duplication
Despite the advances made in targeted therapies for BRAFV600E
melanoma, drug resistance continues to be a major obstacle for
achieving durable clinical responses. To illustrate the utility of this
PDX platform, we set out to screen for resistance mechanisms.
We focused on those that can be discovered at the protein level,
in other words, using analyses requiring substantial amounts of
melanoma tumor material. Thus, we took advantage of our PDX
collection serving as an unlimited source for this purpose.
In addition to the previously identified resistance mechanisms
described above, we noted that several PDXs derived from ve-
murafenib-resistantmelanomasexpressedanunusualBRAFV600E
protein, which migrated in an SDS-PAGE gel at an apparent
molecular weight of 140 kDa. It was recognized by both the
BRAFV600E- and the BRAFNT-specific antibodies (Figure 2A,
M048R2.X1; Figure 5B, M010R.X1, M033R.X1, and M063R.X1).
Strikingly, none of the pre-treatment PDXs showed expression
of this abnormal BRAFV600E protein (Figure S5B). Furthermore,
we discovered similar BRAF proteins in two cell lines that had ac-
quired resistance to MAPK pathway inhibition in vitro (PLX4720-
resistant A375R and dabrafenib/trametinib double-resistant [DR]
888mel) (Figure 6A). Importantly, this abnormal BRAFV600E protein
also was detected in corresponding patients samples of the
PDXs expressing this 140-kDa BRAFV600E protein (Figure 6B),
excluding that this was due to an in vitro or PDX artifact.
To unmask the identity of this apparently common 140-kDa
BRAFV600E protein, we performed whole-genome sequencing
(WGS). We observed that resistant melanoma cells harbored
genomic rearrangements and partial duplication of the BRAF
genomic locus: the first breakpoint was located in the intron be-
tween exons 9 and 10 of BRAFT1799A, while the second break-
point had occurred in the intron between exons 18 and 19. The
resulting duplication contained exons 10–18 of the BRAFT1799A
gene, which harbors the kinase domain (Figure 6C; Figures
S6A–S6F). This was confirmed by PCR using primers specifically
for each breakpoint (Figure 6D).We also observed a larger ampli-
fication on chromosome 7 of 888melDR, raising the possibility
that the locus containing BRAFT1799A with the kinase domain
duplication was amplified specifically during resistance acquisi-
tion (Figures 6E and 6F; Figures S6C and S6D).
To confirm that the duplication of the BRAFT1799A kinase
domain-encoding region results in the production of a
BRAFV600E protein harboring a duplication of its kinase domain
(hereafter BRAFV600E/DK), we performed RNA sequencing on
the four PDXs that expressed the 140-kDa protein. This re-
vealed that, in three of the four cases, the fusion between exon
18 and exon 10 had occurred at 18 bp 50 to the stop codon in
exon 18 and at the start at exon 10 (Figure 6G). This location in
exon 18 recently was identified as a splice donor site (Figure 6G),
which is used by melanoma cells to splice to an alternative X1 30
UTR localized in exon 19 (Marranci et al., 2015). Melanoma cells
can thus express BRAFwith a normal 30 UTR (BRAF-N) or with an
alternative X1 30 UTR (BRAF-X1, Figure 6G).This raised the possibility that, resulting from the genomic re-
arrangement, the BRAFV600E/DK-expressing tumors use this
alternative splice donor site in exon 18 to splice to the next
exon 10. We validated this predicted fusion on mRNA by RT-
PCR, using a forward primer in exon 18 and a reverse primer in
exon 10 (Figure 6H). This confirmed the presence of
BRAFV600E/DK in three PDXs (M033R.X1, M063R.X1, and
M048R2.X1) that showed the 140-kDa band on immunoblot-
ting (Figure 6A), as well as in two vemurafenib-resistant cell lines
(A375R and 888melDR). Also, we confirmed the location of the
fusion by Sanger sequencing (Figure 6I). Furthermore, using
RNA-sequencing data of an independent set of MAPK pathway
inhibition- resistant melanomas (Hugo et al., 2015), we identified
the BRAFV600E/DK in four of 44 resistant tumors (Table S6), in
which no other genomicmechanismwas found to explain the ac-
quired resistance.
To validate the identity and configuration of BRAFV600E/DK
independently at the protein level, we performed immunoprecip-
itation (IP) for BRAF on the 888melDR cell line, which showed
very high expression of the endogenous BRAFV600E/DK protein.
The samples were run on an SDS-PAGE gel from which the
140-kDa band was excised and subjected to mass spectrom-
etry. The result confirmed the findings from the genetic analyses
(Figure S7). Taken together, our data indicate that the genomic
breakpoint can occur anywhere between exons 18 and 19 and
that the tumors use an alternative splice donor site within exon
18 to splice to the next exon (which is exon 10 in the case of
the BRAFV600E/DK). This configuration allows for the natural
stop codon in exon 18 to remain intact, as it is removed by
splicing, resulting in an in-frame kinase domain duplication.
BRAFV600E/DK Is Responsible for Resistance to BRAFi
This is a hitherto unidentified mechanism that may cause resis-
tance to BRAFi. Therefore, we examined whether specific deple-
tion of BRAFV600E/DK, but not BRAFV600E, would result in restora-
tion of BRAF inhibitor sensitivity. We designed small hairpin
RNAs (shRNAs) specifically targeting the region between exons
18 and 10 in the BRAFV600E/DK-encoding mRNA. As expected,
these shRNAs depleted the BRAFV600E/DK protein from the
A375R orM063R.X1 cells, but not the BRAFV600E protein (Figures
7A and 7B). Only when BRAFV600E/DK was silenced was BRAFi
capable of decreasing p-ERK levels. Functional validation of
this observation in a colony formation assay revealed that
BRAFV600E/DK depletion increased sensitivity to BRAFi, in a
dose-dependent manner. These results indicate that specific
knockdown of BRAFV600E/DK sensitizes tumor cells to BRAFi
(Figures 7C and 7D).
To determine whether BRAFV600E/DK hyperactivates ERK, we
overexpressed its cDNA in HEK293T cells. As expected, this re-
sulted in the expression of a 140-kDa protein, which co-migrated
with the BRAFV600E/DK protein seen in resistant PDXs and cell
lines (Figures 6A and 7E). Indeed, BRAFV600E/DK expression re-
sulted in hyperactivation of ERK (Figure 7E). In agreement with
the idea that BRAFV600E/DK constitutively fuels the MAPK
pathway even in the presence of BRAF inhibitor, we observed
that, upon exposure to vemurafenib, BRAFV600E/DK-expressing
cells maintained higher levels of active ERK than cells producing
BRAFV600E (Figure 7E).Cell Reports 16, 263–277, June 28, 2016 271
Figure 6. Resistance Mechanism to BRAFi Involving Duplication of the Kinase Domain of BRAFV600E Discovered in PDX Panel
(A) Immunoblotting for BRAF using a set of four PDXs and two in vitro generated melanoma cell lines resistant for PLX4720 (A375R) or dabrafenib/trametinib
(888melDR). Tubulin is used as a loading control. BRAFNT, antibody recognizing an epitope encoded by exons 2–3 of BRAF; BRAFV600E, antibody recognizing
specifically the BRAFV600E epitope.
(B) Immunoblotting for BRAF on patient samples of vemurafenib-resistant lesions is shown.
(C) Representation of BRAFV600E and BRAFV600E/DK at the genomic level. Arrows indicate the introns where the breakpoints are localized. Black vertical bars,
exons; horizontal bars, introns.
(D) Validation of specific genomic breakpoints is shown.
(E) DNA copy-number alterations in the 888melDR relative to 888mel cell line for chromosome 7, with magnification of the amplified region and further
magnification of the BRAF locus, are shown.
(F) Fluorescence in situ hybridization (FISH) of 888mel and 888melDRcell line, using either aBRAFprobe (red) or a chromosome7centromere probe (green), is shown.
(G) Illustration of BRAFV600E- and BRAFV600E/DK-encoding mRNA. Upper row indicates BRAFV600E with normal 30 UTR (BRAFV600EN), middle row indicates
BRAFV600E with alternative X1 30 UTR (BRAFV600EX1), and bottom row indicates BRAFV600E/DK. Green dashed line indicates splice donor site localized within exon
18, which can be used for alternative 30 UTR splicing.
(H) PCR product using a forward primer in exon 18 and a reverse primer in exon 10 validates the presence of BRAFV600E/DK. As a control, primers in exon 9
(forward) and exon 10 (reverse) were used.
(I) Sanger sequencing of PCR product obtained in (H) is shown.
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Figure 7. BRAFV600E/DK Is Responsible for
Resistance to BRAFi
(A and B) Immunoblotting of A375R (A) or
M063R.X1 (B) cells infected with either scrambled
shRNAs (scr) or two different shRNAs specifically
targeting the BRAFV600E/DK. Cells were treated
with indicated concentrations of inhibitor.
(C andD)Colony formationassayswithA375R (C) or
M063R.X1 (D) cells infected with either scrambled
shRNAs (scr) or two different shRNAs specifically
targeting theBRAFV600E/DK-encodingRNA (1 and2).
Cells were treated for 7 days with control vehicle or
1, 3, 5, 7, or 10mMPLX4720or vemurafenib.Graphs
depict the normalization of six independent experi-
ments. Unpaired t test was performed for each
concentration of drug (*p < 0.05, **p < 0.01, and
***p < 0.001). Error bars indicate SEM.
(E) Immunoblotting of HEK293T cells transfected
with empty vector or a vector with BRAFV600E or
BRAFV600E/DK, treated with vehicle or 1, 3, or 5 mM
vemurafenib, is shown.
(F) Treatment of A375R and PDX-derived cell line
M063R.X1 with increasing concentrations of ve-
murafenib (0.255 mM) or pan-RAF inhibitor
LY3009120 (10 nM1 mM) is shown.
(G and H) Treatment of two PDXs (M048R2.X2 and
M063R.X2) that express the BRAFV600E/DK with
30 mg/kg dabrafenib or 15 mg/kg LY3009120
(n = 8 tumors/group). Graphs represent tumor
volume and dashed lines indicate start of treat-
ment. Unpaired t test was performed at the last
time point (*p < 0.05 and ***p < 0.005). Error bars
indicate SD. Lower part depicts the immu-
noblotting for p-ERK and BRAF on M048R2.X2
and M063R.X2, treated with either dabrafenib or
LY3009120 (each lane represents a tumor derived
from an individual mouse).
(I) Immunoblotting for basic levels (vehicle treated)
of p-ERK and p-AKT inM063R.X2 andM048R2.X2
(each lane represents a tumor derived from an in-
dividual mouse) is shown.BRAFV600E/DK Melanomas Are Sensitive to Pan-RAF
Dimerization Inhibition
Finally, having established that BRAFV600E/DK accounts for
BRAFi resistance in melanoma, we wished to identify a treat-
ment capable of targeting cells harboring this mutant.
Recently, Peng et al. (2015) have shown that a new pan-
RAF dimerization inhibitor (LY3009120) inhibits various forms
of BRAF dimers, including the previously described p61
BRAF isoform (Peng et al., 2015; Poulikakos et al., 2011).
We treated two cell lines (A375R and PDX-derived cell
line M063R.X1), both of which harbored BRAFV600E/DK, with
LY3009120. Compared to treatment with vemurafenib, these
cell lines were highly sensitive to treatment with LY3009120
(Figure 7F).CeNext we tested the effect of the
LY3009120 compound in vivo, using
two PDXs (M063R.X2 and M048R2.X2)
that had acquired the BRAFV600E/DK as
resistance mechanism (Figure 6A). BothPDXs were treated either with the BRAF inhibitor dabrafenib, to
which they were completely resistant (Figures 7G and 7H), or
the pan-RAF dimerization inhibitor LY3009120. LY3009120
treatment of M063R.X2 resulted in an effective inhibition of
p-ERK and thereby stable disease (Figure 7G). In contrast,
upon LY3009120 treatment, M048R2.X2 displayed delayed
tumor outgrowth only (Figure 7H). As shown previously, resis-
tance mechanisms in PDX samples can be heterogeneous
(Kemper et al., 2015; Van Allen et al., 2014). Moreover, above
we described that M048R2.X2 harbors an AKT3L51R mutation
in addition to the BRAFV600E/DK mutation (Figure S4C), which
conceivably explains the reduced sensitivity to the pan-
RAF dimerization inhibitor: the AKT3L51R mutation fuels the
PI3K/AKT pathway, which may reduce the effect of BRAFi.ll Reports 16, 263–277, June 28, 2016 273
Indeed, AKT signaling was much more active in the M048R2.X2
PDX (Figure 7I), explaining its only partial sensitivity to
LY3009120.
These results warrant clinical validation of LY3009120 for
treating melanoma patients harboring a BRAFV600E/DK mutation.
More generally, these findings highlight one key feature of our
PDX platform.
DISCUSSION
Here we present a comprehensive and well-characterized
PDX collection comprising 89 metastatic human melanomas,
including a set of matched pre-treatment/post-relapse pairs.
Tumor tissue for this platform was derived from BRAFV600E,
NRASQ61, and BRAFWT/NRASWT metastatic melanomas. Sam-
ples were acquired before the start of targeted therapy and/or af-
ter resistance had occurred. By analyzing biomarker expression,
chromosomal aberrations, and RNA expression, we demon-
strate that these PDXs recapitulate the key characteristics of
the corresponding patients’ tumors. In addition, we show that
PDXs derived from vemurafenib-resistant melanomas harbor a
plethora of established clinical resistance mechanisms: (1) we
have identified previously established resistance-causing muta-
tions, amplifications, and protein expression changes in a cohort
of treatment-refractory PDXs; (2) we show that resistance to tar-
geted therapy is maintained in PDXs; (3) we present evidence for
reversal and adaption of drug response similar to what is seen in
the clinic; and (4) we observed genetic heterogeneity in resis-
tance mechanisms in PDXs, similar to what is observed in the
clinic. Although not explored here, adding to the versatility of
the PDX platform, several fundamental aspects of melanoma
progression, like phenotype switching (Hoek et al., 2006; Verfail-
lie et al., 2015), are better studied in an in vivo setting. Finally, to
illustrate the power and utility of this platform, we have taken
advantage of its limitless tumor resource, in contrast to patients’
biopsies. Screening in PDX cell lysates for BRAF proteins with
aberrant molecular weights, we identified a kinase domain
duplication mutant of BRAFV600E, which drives vemurafenib
resistance.
While several resistance mechanisms have been identified
previously thanks to the efforts of many laboratories (Nazarian
et al., 2010; Paraiso et al., 2011; Poulikakos et al., 2011; Shi
et al., 2012, 2014a; Das Thakur et al., 2013; Wagenaar et al.,
2014; Wagle et al., 2011), we show here that a specific genetic
duplication encoding the kinase domain of BRAFV600E causes
resistance to MAPK pathway inhibition. Remarkably, the
genomic rearrangement, which results from intronic breaks be-
tween exons 9 and 10 and between exons 18 and 19, leaves
the original stop codon present in exon 18 intact. As melanoma
cells seem to preferentially use the alternative splice donor site in
exon 18 to splice to the alternative X1 30 UTR in exon 19 (and thus
use the X1 stop codon) (Marranci et al., 2015), this conceivably
explains why cells carrying the genomic duplication of the kinase
domain use this splice donor site to produce the BRAFV600E/DK
protein. This may imply that the splicing event can be induced
by drug exposure; this would provide a selective advantage,
whereas expression of BRAFV600E/DK in the absence of BRAFi
would not.274 Cell Reports 16, 263–277, June 28, 2016Previously, others have shown that duplication of the kinase
domain of RTKs, like EGFR (Gallant et al., 2015; Ozer et al.,
2010) or FGFR1 (Zhang et al., 2015), drives oncogenicity in glio-
blastoma, lung cancer, and gliomas, respectively. Recently,
wild-type BRAF with a duplicated kinase domain was detected
in a neuroblastoma tumor after chemotherapy (Eleveld et al.,
2015), but such an event has not yet been implicated in acquired
resistance to targeted therapy. Further research will be required
to unravel the mechanism of how BRAFV600E/DK functions at a
molecular level. Of note, we have attempted to overexpress
the BRAFV600E/DK in BRAFV600E and NRASWTBRAFWT melanoma
cell lines, but we observed that cells quickly shut down the
expression of this mutant, thereby precluding the study of any
functional consequences. Melanomas harboring BRAFV600E/DK
to drive resistance have adapted over the course of acquiring
resistance to express optimal levels of BRAFV600E and
BRAFV600E/DK, and perhaps additional rewiring of signaling net-
works. Apparently, for this particular mutation, this is difficult to
recapitulate in the lab by introducing this mutant freshly into
melanoma cells that previously were not dependent on it. This
is not a general pattern; for example, we have shown previously
that ectopic expression of MEK1T55insdelRT is easily achieved and
drives drug resistance (Kemper et al., 2015).
Using an inhibitor that targets the BRAFV600E homodimers
(Peng et al., 2015), we were able to eliminate BRAFV600E/DK
melanoma cells and effectively inhibited tumor growth of PDXs
in vivo. As we identified the BRAFV600E/DK as a resistance mech-
anism in 10% of PDXs and patient samples, this pan-RAF
dimerization inhibitor may offer a clinical opportunity for this
particular subgroup of patients who have required resistance
to (combined) inhibitors of the BRAF pathway, arguing that
screening for this subset of patients could be beneficial.
We conclude that the PDX platform presented here reflects
the original melanomas in patients very well with respect to
several key characteristics, including resistance mechanisms.
This platform therefore provides a relevant and comprehensive
suite of well-characterized treatment-naive and -resistant mel-
anomas, representing an invaluable toolbox for studying funda-
mental aspects of melanoma biology and for the development,
validation, and optimization of melanoma (combinatorial) treat-
ments, to further improve the perspective on melanoma
patients.
EXPERIMENTAL PROCEDURES
Patient Samples, Animals, and PDXs
The collection and use of human tissue was approved by the Medical Ethical
Review Board of the Antoni van Leeuwenhoek. Animal experiments were
approved by the animal experimental committee of the institute and performed
according to Dutch law. Human tumor tissue was obtained either by excision
during surgery or using a 14-gauge biopsy needle. Tumor fragments of
5 mm3 were used for subcutaneous transplantation into NSG mice, which
was performed under anesthesia. Before reaching the maximum allowed tu-
mor size, mice were sacrificed, tumors were removed, and tumor pieces
were (1) fixed in formalin and embedded in paraffin; (2) snap-frozen and stored
at 80C for further analyses; (3) cryopreserved in 10% fetal calf serum (FCS)
in DMSO and stored at80C for additional passages; and (4) re-transplanted
into a new set of NSG mice. Treatment was performed with dabrafenib (Ab-
mole, 30 mg/kg daily) or LY3009120 (Selleck, 15 mg/kg twice daily [b.i.d.])
by oral gavage. Inhibitors were dissolved in DMSO and further diluted in the
vehicle 0.5% hydroxypropylmethylcellulose (Sigma-Aldrich) and 0.2% Tween
80 in (pH 8.0) distilled H20.
IHC
PDX pieces were fixed in formalin and embedded in paraffin. Slides were
stained for H&E, S100 (Z031129, DakoCytomation), gp-100 (MS-264-S0,
Thermo Scientific), melanA (M719629, DakoCytomation), tyrosinase (T311,
9319, Cell Signaling Technology), and p-ERK1/2 (E10, 4370, Cell Signaling
Technology) by our in-house Animal Pathology facility. The NKI-AVL Core
Facility Molecular Pathology & Biobanking (CFMPB) provided the NKI-AVL
Biobank patient material and performed the BRAFV600E (VE1, Spring Biosci-
ence) staining according to the manufacturer’s protocol.
Immunoblotting and Antibodies
Immunoblotting was performed as described previously (Possik et al., 2014).
The following antibodies were used: p-ERK1/2 (E10, 9106), ERK1/2 (9102),
p-MEK (41G9, 9154), MEK (L38C12, 4694), p-AKT (D9E, 4060), and p-MET
(Tyr1234, 3077) from Cell Signaling Technology; BRAFV600E (VE1) from Spring
Bioscience; B-RAF (F7), EGFR (1005), MET (C-28), PDGFR (C20), AXL (C-20),
and PTEN (A2B1) from Santa Cruz Biotechnology; MITF (ab12039) from Ab-
cam; and vinculin (V9131) from Sigma.
Cell Culture, Transfection, and Virus Production
Melanoma cell lines and HEK293T cells were cultured in DMEM containing
fetal bovine serum (FBS) (Sigma), 2 mM glutamine, 100 U/ml penicillin, and
0.1 mg/ml streptomycin (all Gibco) under standard conditions. Resistant
cell lines were generated by treatment with increasing concentrations of
PLX4720 (Selleck Chemicals, up to 3 mM) or the combination of dabrafenib
(GSK2118436, Abmole, up to 0.5 mM)/trametinib (GSK1120212, S2673, Sell-
eck Chemicals, up to 50 nM). Transfections and production of lentivirus
were performed as described previously (Vredeveld et al., 2012). A375R cells
were infected and selected with puromycin (1 mg/ml). For the colony formation
assays, 20,000 cells were seeded in six-well plates and indicated concentra-
tions of PLX4720, vemurafenib, or LY3009120 were added the next day. Cells
were stained by 0.1% crystal violet in 50%methanol and 50%H20. After stain-
ing, de-staining by 10%acetic acid was used to quantify the number of stained
cells. Color intensity was measured at 590 nm and values were normalized
to DMSO control. For immunoblotting, cells were treated for 24 hr with the
indicated concentrations of BRAFi.
qPCR, Sanger Sequencing, and Validation of the Presence/Cloning
of BRAFV600E/DK and shRNA Generation
All primers and hairpin sequences are described in Table S7. BRAFV600E/DK
was cloned from the 888melDR cell line into a TOPO TA-cloning vector
(450071, Invitrogen); we used the restriction site XbaI and SwaI to clone
BRAFV600E/D into the pCDH vector. BRAFV600E/DK shRNAs were designed at
the junction region between exons 18 and 10.
Statistical Testing
The data of in vivo experiments were analyzed at the last time point by an
unpaired t test using the Prism software. For the colony formations assays,
six independent experiments were performed. Data were normalized to the
scr control for each concentration of the drug. Unpaired t tests were used (in
Prism software) to compare the effect between the scr and the two hairpins
for each concentration of the drug.
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